Copyright
©2012 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jun 21, 2012; 18(23): 2966-2972
Published online Jun 21, 2012. doi: 10.3748/wjg.v18.i23.2966
Published online Jun 21, 2012. doi: 10.3748/wjg.v18.i23.2966
Impact of ribavirin dose on retreatment of chronic hepatitis C patients
Christiane Stern, Michelle Martinot-Peignoux, Marie Pierre Ripault, Nathalie Boyer, Corinne Castelnau, Dominique Valla, Patrick Marcellin, Service d’Hépatologie and INSERM U773-CRB3, Hôpital Beaujon, University Paris-Diderot, 92110 Clichy, France
Author contributions: Stern C, Martinot-Peignoux M and Marcellin P designed the study; Stern C and Ripault MP collected the data; Martinot-Peignoux M performed the measurements and analyses; Stern C performed statistical analyses; Boyer N, Castelnau C and Valla D contributed to the interpretation of data; Stern C and Marcellin P drafted the manuscript; and all authors have read and approved the final manuscript.
Supported by Assistance publique-Hôpitaux de Paris, INSERM U773-CRB3 and University Paris-Diderot; Fees from Roche, Schering Plough, Novartis, Gilead Sciences, BMS, MSD, Vertex, Tibotec, Biolex, to Marcellin P; Zymmogenetics and grants from Gilead Sciences, Roche and Schering Plough
Correspondence to: Patrick Marcellin, MD, Service d’Hépatologie and INSERM U773-CRB3, Hôpital Beaujon, University Paris-Diderot, Pavillon Abrami, 100 Boulevard du Général Leclerc, 92110 Clichy, France. patrick.marcellin@bjn.aphp.fr
Telephone: +33-1-40875338 Fax: +33-1-47309440
Received: October 2, 2011
Revised: February 15, 2012
Accepted: February 26, 2012
Published online: June 21, 2012
Revised: February 15, 2012
Accepted: February 26, 2012
Published online: June 21, 2012
Core Tip